Detalles de la búsqueda
1.
A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study.
Gynecol Oncol
; 138(1): 30-5, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25887099
2.
A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.
Gynecol Oncol
; 126(3): 369-74, 2012 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-22659190
3.
A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study.
Gynecol Oncol
; 124(1): 48-52, 2012 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-21996263
4.
Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study.
J Clin Oncol
; 40(35): 4119-4128, 2022 12 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35759733
5.
Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer.
Gynecol Oncol
; 94(2): 533-9, 2004 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-15297200
Resultados
1 -
5
de 5
1
Próxima >
>>